EUCTR2016-001879-73-Outside-EU/EEA进行中（未招募）1 期
Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females aged 12 to 16 years with a clinical diagnosis of symptomatic GERD or suspected or endoscopically proven GERD.
- •2. Patients who have ever been treated with, or are currently receiving proton pump inhibitors (PPIs),histamine receptor (H2) blockers, or antacids are eligible (as long as they can go off PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing; exclusion criteria 5 and 6). Also, patients should be able to go off PPI therapy for two weeks at the end active drug treatment.
- •3. Children with stable asthma/reactive airways disease on stable treatment regimens are eligible.
- •4. Children on stable doses of allergy, antiepileptic, antidepressant, and attention deficit disorder medicines are eligible.
- •5. Patients must be able and willing to swallow the test drug tablet intact. The ability of the child to swallow an intact tablet must be confirmed by the site at Screening.
- •6. The patient is willing and able to give assent to participate.
- •7. The patient's parent or guardian gives written informed consent.
- •8. Post-pubertal females will be required to be abstinent during the course of the study.
- •9. Clinically insignificant laboratory findings.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 111
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Evidence of significant hepatic, renal, respiratory, endocrine, immune, infectious, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
- •2. History of primary esophageal motility disorders or systemic condition affecting the esophagus (eg, scleroderma, esophageal infections).
- •3. History of eosinophilic esophagitis, persistent milk protein allergy, or allergic gastroenteropathy. History or current presence of peptic ulcers; current presence of Helicobacter pylori.
- •4. History of definitive acid-lowering surgery, previous esophageal surgery, or esophageal stricture is disallowed. History of fundoplication or feeding tube insertion is allowed.
- •5. Treatment with full therapeutic doses of H2-receptor antagonists or sucralfate within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor), except for cimetidine, which must be discontinued for at least seven days prior to dosing.
- •6. Treatment with a proton pump inhibitor within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor).
- •7. Inability to have 2-week PPI therapy-free period at end of active drug treatment.
- •8. Pregnancy or lactation.
- •9. Known or suspected drug addiction or alcohol abuse and/or a positive urine drug screen not explained by medication list; occasional alcohol or tobacco use is not an exclusion criterion.
- •10. Unwilling or unable to abide by the requirements of the study or violating the prohibitions and restrictions of the study.
- •11. Any condition which would make the patient, in the opinion of the Investigator or Sponsor, unsuitable for the study.
- •12. Participation in another investigational drug study within one month prior to dosing.
- •13. A history of allergy/sensitivity to proton pump inhibitors or to their inactive ingredients.
研究者
相似试验
尚未招募
Unknown
Clinical Efficacy of rabeprazole in patients treated with dual antiplatelet agents including potent P2Y12 inhibitors after percutaneous coronary intervention for acute coronary syndromeKCT0008344Yonsei University Yongin Severance Hospital50
已完成
不适用
Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD).early gastric cancer or gastric adenomaJPRN-UMIN000000688The University of Tokyo, Department of Gastroenterology55
未知
Unknown
Rabeprazole specific clinical experience investigation for the long-term combination therapy with low-dose aspiriGastric ulcer, Duodenal ulcerJPRN-jRCT1080222833Eisai Co., Ltd.1,400
尚未招募
不适用
Prevention of change of gastric Ph(acidity) and volume during laparoscopic cholecystectomy(removal of diseased gall bladder due to gall stone disease) by intravenous rabeprazole(Antacid)in patients during general anaesthesia to minimize risk of gastric aspiration and injury to lungsCTRI/2022/12/048045VCSGGMS and RI Srikot Srinagar Garhwal Uttarakhand
已完成
不适用
The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic sclerodermareflux esophagitis associated with systemic sclerodermaJPRN-UMIN000020701Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University40